Pharmacogenetics of FSH action in the female

Alessandro Conforti, Alberto Vaiarelli, Danilo Cimadomo, Francesca Bagnulo, Stefania Peluso, Luigi Carbone, Francesca Di Rella, Giuseppe De Placido, Filippo Maria Ubaldi, Ilpo Huhtaniemi, Carlo Alviggi

Research output: Contribution to journalArticle

Abstract

The purpose of a pharmacogenomic approach is to tailor treatment on the basis of an individual human genotype. This strategy is becoming increasingly common in medicine, and important results have been obtained in oncologic and antimicrobial therapies. The rapid technological developments and availability of innovative methodologies have revealed the existence of numerous genotypes that can influence the action of medications and give rise to the idea that a true “individualized” approach could become in the future a reality in clinical practice. Moreover, compared to the past, genotype analyses are now more easily available at accessible cost. Concerning human reproduction, there is ample evidence that several variants of gonadotropins and their receptors influence female reproductive health and ovarian response to exogenous gonadotropins. In more detail, variants in genes of follicle-stimulating hormone β-chain (FSH-B) and its receptor (FSH-R) seem to be the most promising candidates for a pharmacogenomic approach to controlled ovarian stimulation in assisted reproductive technologies. In the present review, we summarize the evidence regarding FSH-B and FSH-R variants, with special reference to their impact on reproductive health and assisted reproductive technology treatments.

Original languageEnglish
Article number398
JournalFrontiers in Endocrinology
Volume10
Issue numberJUN
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Pharmacogenetics
Assisted Reproductive Techniques
Genotype
Reproductive Health
Gonadotropin Receptors
Ovulation Induction
Follicle Stimulating Hormone
Gonadotropins
Reproduction
Therapeutics
Medicine
Costs and Cost Analysis
Genes

Keywords

  • Assisted reproductive technology
  • FSH
  • FSH receptor
  • Genetic variants
  • IVF
  • Mutations
  • Ovarian stimulation
  • Polymorphisms

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Conforti, A., Vaiarelli, A., Cimadomo, D., Bagnulo, F., Peluso, S., Carbone, L., ... Alviggi, C. (2019). Pharmacogenetics of FSH action in the female. Frontiers in Endocrinology, 10(JUN), [398]. https://doi.org/10.3389/fendo.2019.00398

Pharmacogenetics of FSH action in the female. / Conforti, Alessandro; Vaiarelli, Alberto; Cimadomo, Danilo; Bagnulo, Francesca; Peluso, Stefania; Carbone, Luigi; Rella, Francesca Di; De Placido, Giuseppe; Ubaldi, Filippo Maria; Huhtaniemi, Ilpo; Alviggi, Carlo.

In: Frontiers in Endocrinology, Vol. 10, No. JUN, 398, 01.01.2019.

Research output: Contribution to journalArticle

Conforti, A, Vaiarelli, A, Cimadomo, D, Bagnulo, F, Peluso, S, Carbone, L, Rella, FD, De Placido, G, Ubaldi, FM, Huhtaniemi, I & Alviggi, C 2019, 'Pharmacogenetics of FSH action in the female', Frontiers in Endocrinology, vol. 10, no. JUN, 398. https://doi.org/10.3389/fendo.2019.00398
Conforti A, Vaiarelli A, Cimadomo D, Bagnulo F, Peluso S, Carbone L et al. Pharmacogenetics of FSH action in the female. Frontiers in Endocrinology. 2019 Jan 1;10(JUN). 398. https://doi.org/10.3389/fendo.2019.00398
Conforti, Alessandro ; Vaiarelli, Alberto ; Cimadomo, Danilo ; Bagnulo, Francesca ; Peluso, Stefania ; Carbone, Luigi ; Rella, Francesca Di ; De Placido, Giuseppe ; Ubaldi, Filippo Maria ; Huhtaniemi, Ilpo ; Alviggi, Carlo. / Pharmacogenetics of FSH action in the female. In: Frontiers in Endocrinology. 2019 ; Vol. 10, No. JUN.
@article{01da7965434d4da68c7eb8a653c13bf9,
title = "Pharmacogenetics of FSH action in the female",
abstract = "The purpose of a pharmacogenomic approach is to tailor treatment on the basis of an individual human genotype. This strategy is becoming increasingly common in medicine, and important results have been obtained in oncologic and antimicrobial therapies. The rapid technological developments and availability of innovative methodologies have revealed the existence of numerous genotypes that can influence the action of medications and give rise to the idea that a true “individualized” approach could become in the future a reality in clinical practice. Moreover, compared to the past, genotype analyses are now more easily available at accessible cost. Concerning human reproduction, there is ample evidence that several variants of gonadotropins and their receptors influence female reproductive health and ovarian response to exogenous gonadotropins. In more detail, variants in genes of follicle-stimulating hormone β-chain (FSH-B) and its receptor (FSH-R) seem to be the most promising candidates for a pharmacogenomic approach to controlled ovarian stimulation in assisted reproductive technologies. In the present review, we summarize the evidence regarding FSH-B and FSH-R variants, with special reference to their impact on reproductive health and assisted reproductive technology treatments.",
keywords = "Assisted reproductive technology, FSH, FSH receptor, Genetic variants, IVF, Mutations, Ovarian stimulation, Polymorphisms",
author = "Alessandro Conforti and Alberto Vaiarelli and Danilo Cimadomo and Francesca Bagnulo and Stefania Peluso and Luigi Carbone and Rella, {Francesca Di} and {De Placido}, Giuseppe and Ubaldi, {Filippo Maria} and Ilpo Huhtaniemi and Carlo Alviggi",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fendo.2019.00398",
language = "English",
volume = "10",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - Pharmacogenetics of FSH action in the female

AU - Conforti, Alessandro

AU - Vaiarelli, Alberto

AU - Cimadomo, Danilo

AU - Bagnulo, Francesca

AU - Peluso, Stefania

AU - Carbone, Luigi

AU - Rella, Francesca Di

AU - De Placido, Giuseppe

AU - Ubaldi, Filippo Maria

AU - Huhtaniemi, Ilpo

AU - Alviggi, Carlo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The purpose of a pharmacogenomic approach is to tailor treatment on the basis of an individual human genotype. This strategy is becoming increasingly common in medicine, and important results have been obtained in oncologic and antimicrobial therapies. The rapid technological developments and availability of innovative methodologies have revealed the existence of numerous genotypes that can influence the action of medications and give rise to the idea that a true “individualized” approach could become in the future a reality in clinical practice. Moreover, compared to the past, genotype analyses are now more easily available at accessible cost. Concerning human reproduction, there is ample evidence that several variants of gonadotropins and their receptors influence female reproductive health and ovarian response to exogenous gonadotropins. In more detail, variants in genes of follicle-stimulating hormone β-chain (FSH-B) and its receptor (FSH-R) seem to be the most promising candidates for a pharmacogenomic approach to controlled ovarian stimulation in assisted reproductive technologies. In the present review, we summarize the evidence regarding FSH-B and FSH-R variants, with special reference to their impact on reproductive health and assisted reproductive technology treatments.

AB - The purpose of a pharmacogenomic approach is to tailor treatment on the basis of an individual human genotype. This strategy is becoming increasingly common in medicine, and important results have been obtained in oncologic and antimicrobial therapies. The rapid technological developments and availability of innovative methodologies have revealed the existence of numerous genotypes that can influence the action of medications and give rise to the idea that a true “individualized” approach could become in the future a reality in clinical practice. Moreover, compared to the past, genotype analyses are now more easily available at accessible cost. Concerning human reproduction, there is ample evidence that several variants of gonadotropins and their receptors influence female reproductive health and ovarian response to exogenous gonadotropins. In more detail, variants in genes of follicle-stimulating hormone β-chain (FSH-B) and its receptor (FSH-R) seem to be the most promising candidates for a pharmacogenomic approach to controlled ovarian stimulation in assisted reproductive technologies. In the present review, we summarize the evidence regarding FSH-B and FSH-R variants, with special reference to their impact on reproductive health and assisted reproductive technology treatments.

KW - Assisted reproductive technology

KW - FSH

KW - FSH receptor

KW - Genetic variants

KW - IVF

KW - Mutations

KW - Ovarian stimulation

KW - Polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=85069003824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069003824&partnerID=8YFLogxK

U2 - 10.3389/fendo.2019.00398

DO - 10.3389/fendo.2019.00398

M3 - Article

AN - SCOPUS:85069003824

VL - 10

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

IS - JUN

M1 - 398

ER -